Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    The effects of SGLT2-inhibition in patients with non-diabetic chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones

    Summary
    EudraCT number
    		 2019-004467-50
    Trial protocol
    		 DK  
    Global end of trial date
    22 Dec 2022

    Results information
    Results version number
    		 v1(current)
    This version publication date
    22 Feb 2025
    First version publication date
    22 Feb 2025
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    SFN-3-2019
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Sponsor organisation address
    Hospitalparken 15, Herning, Denmark, 7400
    Public contact
    Steffen Flindt Nielsen, University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro, 0045 78436588, steffen.nielsen@midt.rm.dk
    Scientific contact
    Steffen Flindt Nielsen, University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro, 0045 78436588, steffen.nielsen@midt.rm.dk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    22 Dec 2022
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    22 Dec 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    22 Dec 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To examine the effects of SGLT2-inhibition versus placebo on renal hemodynamics in patients with non-diabetic chronic kidney disease
    Protection of trial subjects
    NA
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    01 Mar 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Denmark: 21
    Worldwide total number of subjects
    21
    EEA total number of subjects
    21
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    9
    From 65 to 84 years
    12
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 -

    Pre-assignment period milestones
    Number of subjects started
    		 21
    Number of subjects completed
    		 21

    Period 1
    Period 1 title
    Empagliflozin
    Is this the baseline period?
    		 No
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Investigator, Monitor, Data analyst, Carer, Subject, Assessor

    Arms
    Arm title
    		 Empagliflozin
    Arm description
    		 -
    Arm type
    		 Experimental

    Investigational medicinal product name
    Empagliflozin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    10 mg x 1 day

    Number of subjects in period 1
    		Empagliflozin
    Started
    21
    Completed
    16
    Not completed
    5
         Consent withdrawn by subject
    3
         Adverse event, non-fatal
    1
         non-compliance
    1
    Period 2
    Period 2 title
    Placebo
    Is this the baseline period?
    		 Yes [1]
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Monitor, Data analyst, Carer, Assessor

    Arms
    Arm title
    		 Placebo
    Arm description
    		 -
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    1 tablet x 1 day

    Notes
    [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.
    Justification: It is a cross over design, where placebo is the "baseline"
    Number of subjects in period 2 [2]
    		Placebo
    Started
    16
    Completed
    16
    Notes
    [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: see above

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 -

    Reporting group values
    		 Placebo Total
    Number of subjects
    		 16 16
    Age categorical
    Units: Subjects
        In utero
    		 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0
        Newborns (0-27 days)
    		 0
        Infants and toddlers (28 days-23 months)
    		 0
        Children (2-11 years)
    		 0
        Adolescents (12-17 years)
    		 0
        Adults (18-64 years)
    		 0
        From 65-84 years
    		 0
        85 years and over
    		 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 66.9 ( 8.2 ) -
    Gender categorical
    Units: Subjects
        Female
    		 7 7
        Male
    		 9 9

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Empagliflozin
    Reporting group description
    		 -
    Reporting group title
    Placebo
    Reporting group description
    		 -

    Primary: Renal Blood flow

    		 Close Top of page
    End point title
    		 Renal Blood flow
    End point description
    End point type
    Primary
    End point timeframe
    at the end of each treatment period
    End point values
    		 Empagliflozin Placebo
    Number of subjects analysed
    16
    16
    Units: ml/min/ccm
        geometric mean (inter-quartile range (Q1-Q3))
    1.17 (0.96 to 1.34)
    1.18 (0.99 to 1.42)
    Statistical analysis title
    		 paired t-test
    Comparison groups
    Empagliflozin v Placebo
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.72
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: GFR

    		 Close Top of page
    End point title
    		 GFR
    End point description
    End point type
    Secondary
    End point timeframe
    at the end of each treatment period
    End point values
    		 Empagliflozin Placebo
    Number of subjects analysed
    16
    16
    Units: ml/min/1.73m2
        geometric mean (inter-quartile range (Q1-Q3))
    30.1 (21.9 to 42.6)
    33.8 (25.7 to 47.1)
    Statistical analysis title
    		 paired t-test
    Comparison groups
    Empagliflozin v Placebo
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.018
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: RVR

    		 Close Top of page
    End point title
    		 RVR
    End point description
    End point type
    Secondary
    End point timeframe
    at the end of each period
    End point values
    		 Empagliflozin Placebo
    Number of subjects analysed
    16
    16
    Units: mmHg/ml/min
        geometric mean (inter-quartile range (Q1-Q3))
    0.42 (0.29 to 0.59)
    0.43 (0.30 to 0.56)
    Statistical analysis title
    		 paired t-test
    Comparison groups
    Empagliflozin v Placebo
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.67
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: systolic blood pressure

    		 Close Top of page
    End point title
    		 systolic blood pressure
    End point description
    End point type
    Secondary
    End point timeframe
    at the end of each period
    End point values
    		 Empagliflozin Placebo
    Number of subjects analysed
    16
    16
    Units: mmHg
        arithmetic mean (standard deviation)
    122 ( 13 )
    126 ( 12 )
    Statistical analysis title
    		 paired t-test
    Comparison groups
    Empagliflozin v Placebo
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.07
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: diastolic blood pressure

    		 Close Top of page
    End point title
    		 diastolic blood pressure
    End point description
    End point type
    Secondary
    End point timeframe
    at the end of each treatment period
    End point values
    		 Empagliflozin Placebo
    Number of subjects analysed
    16
    16
    Units: mmHg
        arithmetic mean (standard deviation)
    77 ( 10 )
    79 ( 9 )
    Statistical analysis title
    		 paired t-test
    Comparison groups
    Empagliflozin v Placebo
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.1
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: TVR

    		 Close Top of page
    End point title
    		 TVR
    End point description
    End point type
    Secondary
    End point timeframe
    at the end of each period
    End point values
    		 Empagliflozin Placebo
    Number of subjects analysed
    16
    16
    Units: dyn*s/m5
        arithmetic mean (standard deviation)
    1678 ( 136 )
    1721 ( 136 )
    Statistical analysis title
    		 paired t-test
    Comparison groups
    Empagliflozin v Placebo
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.03
    Method
    		 t-test, 2-sided
    Confidence interval

    Secondary: heart rate

    		 Close Top of page
    End point title
    		 heart rate
    End point description
    End point type
    Secondary
    End point timeframe
    at the end of each period
    End point values
    		 Empagliflozin Placebo
    Number of subjects analysed
    16
    16
    Units: min-1
        arithmetic mean (standard deviation)
    68 ( 8 )
    69 ( 9 )
    Statistical analysis title
    		 paired t-test
    Comparison groups
    Empagliflozin v Placebo
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.37
    Method
    		 t-test, 2-sided
    Confidence interval

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    from beginning of trial to LPLV+1 Week
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    21
    Reporting groups
    Reporting group title
    total trial
    Reporting group description
    		 total trial

    Serious adverse events
    		 total trial
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 21 (0.00%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    		 total trial
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    8 / 21 (38.10%)
    Cardiac disorders
    Hypotension
         subjects affected / exposed
    2 / 21 (9.52%)
         occurrences all number
    2
    General disorders and administration site conditions
    Dehydration
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1
    Febrile infection
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1
    Vasodilatation
    Additional description: Vasovagal episode
         subjects affected / exposed
    2 / 21 (9.52%)
         occurrences all number
    2
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1
    Renal and urinary disorders
    Renal injury
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1
    Urinary tract infection
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1
    Musculoskeletal and connective tissue disorders
    Pain
    Additional description: 3 hours of pain under the right curvature
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1
    Infections and infestations
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1
    Erysipelas
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1
    Metabolism and nutrition disorders
    Hyponatraemia
         subjects affected / exposed
    1 / 21 (4.76%)
         occurrences all number
    1

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references
    http://www.ncbi.nlm.nih.gov/pubmed/39810756
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:43:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA